When does CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) report earnings?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) will report earnings on 2025-11-10.
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Forecast, Price Target & Analyst Ratings
NASDAQ:CYCCP • US23254L2079
Current stock price
5.05 USD
-0.23 (-4.36%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Nov 10, 2025
- Period
- Q3 / 2025
- EPS Estimate
- -$0.31
- Revenue Estimate
- 25.5K
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $5.05 to mean target of N/A, Based on 6 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
CYCCP was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about CYCCP.
In the previous month the buy percentage consensus was at a similar level.
CYCCP was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Nov 10, 2025
- Period
- Q3 / 2025
- EPS Estimate
- -$0.31
- Revenue Estimate
- 25.5K
- Revenue Q2Q
- 155.00%
- EPS Q2Q
- 99.29%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
CYCCP is expected to report earnings on 11/10/2025. The consensus EPS estimate for the next earnings is -0.31 USD and the consensus revenue estimate is 25.50K USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 420K | 43K -89.76% | 102K 137.21% | 102K | 82.194M 80,482.35% | 120.44M 46.53% | 145.3M 20.64% | 156.78M 7.90% | 162.76M 3.81% | ||
| EBITDA YoY % growth | -27.63M -20.66% | -25.422M 7.99% | -11.998M 52.80% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -27.66M -20.58% | -25.453M 7.98% | -12.004M 52.84% | -9.694M 19.24% | -9.897M -2.09% | 71.988M 827.37% | 110.02M 52.83% | 134.66M 22.40% | 145.92M 8.36% | 151.67M 3.94% | |
| Operating Margin | N/A | -6,060.24% | -27,916.28% | -9,504.00% | -9,703.00% | 87.58% | 91.35% | 92.68% | 93.07% | 93.19% | |
| EPS YoY % growth | -456.00 11.21% | -435.68 4.46% | N/A 99.54% | -1.20 39.49% | -1.14 5.08% | 3.74 427.68% | 5.60 49.59% | 5.40 -3.64% | 5.71 5.86% | 5.80 1.61% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -0.31 99.29% | -0.31 -3.45% |
| Revenue Q2Q % growth | 25.5K 155.00% | 25.5K |
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -2.436M -11.89% | -2.46M -34.59% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
57.16%
EPS Next 5 Year
36.35%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
1,049.89%
Revenue Next 5 Year
385.15%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP / CYCCP Forecast FAQ
Can you provide the consensus estimates for CYCLACEL PHARMACEUTICALS - CYCC 6 PERP next earnings?
The consensus EPS estimate for the next earnings of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) is -0.31 USD and the consensus revenue estimate is 25.50K USD.
Can you provide the analyst count for CYCLACEL PHARMACEUTICALS - CYCC 6 PERP stock?
The number of analysts covering CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) is 6.